{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:23:19Z","timestamp":1772216599627,"version":"3.50.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    The oral cholera vaccine WC-rBS consists of 4 different inactivated strains of\n                    <jats:italic>Vibrio cholerae<\/jats:italic>\n                    (LPS source) admixed with recombinant cholera toxin B subunit. Because of its unique composition and anti-inflammatory properties reported for both CTB and low doses of LPS from other Gram-negative bacteria, we speculated that WC-rBS might have anti-inflammatory potential in a chronic autoimmune disease such as inflammatory bowel diseases. First\n                    <jats:italic>in vitro<\/jats:italic>\n                    endotoxin tolerance experiments showed the surprising WC-rBS potential in the modulation of inflammatory responses on both PBMCs and THP1 cells. WC-rBS was further evaluated in the Dextran Sodium Sulfate colitis mouse model. Administrated orally at different dosages, WC-rBS vaccine was safe and showed immunomodulatory properties when administered in a preventive mode (before and during the induction of DSS colitis) as well as in a curative mode (after colitis induction); with improvement of disease activity index (from 27 to 73%) and histological score (from 65 to 88%). Interestingly, the highest therapeutic effect of WC-rBS vaccine was observed with the lowest dosage, showing even better anti-inflammatory properties than mesalamine; an approved 5-aminosalicylic acid drug for treating IBD patients. In summary, this is the first time that a prophylactic medicine, safe and approved for prevention of an infectious disease, showed a benefit in an inflammatory bowel disease model, potentially offering a novel therapeutic modality for IBD patients.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0283489","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:29:07Z","timestamp":1693229347000},"page":"e0283489","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["An oral cholera vaccine in the prevention and\/or treatment of inflammatory bowel disease"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3307-1027","authenticated-orcid":true,"given":"Marine","family":"Meunier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Spillmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Rousseaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Schwamborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"pone.0283489.ref001","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"AL Franks","year":"2012","journal-title":"Anticancer Res"},{"key":"pone.0283489.ref002","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"SC Ng","year":"2017","journal-title":"The Lancet"},{"key":"pone.0283489.ref003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"SS Seyedian","year":"2019","journal-title":"J Med Life"},{"key":"pone.0283489.ref004","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease","volume":"385","author":"DC Baumgart","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0283489.ref005","first-page":"179","article-title":"Cholera toxin: a paradigm of a multifunctional protein","volume":"133","author":"K Bharati","year":"2011","journal-title":"Indian J Med Res"},{"key":"pone.0283489.ref006","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/toxins7030974","article-title":"Cholera toxin B: one subunit with many pharmaceutical applications","volume":"7","author":"KJ Baldauf","year":"2015","journal-title":"Toxins (Basel)"},{"key":"pone.0283489.ref007","article-title":"Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa","author":"JM Royal","year":"2017","journal-title":"Toxins (Basel)"},{"key":"pone.0283489.ref008","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.4049\/jimmunol.168.4.1730","article-title":"Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinflammatory responsiveness to lipopolysaccharide","volume":"168","author":"V Burkart","year":"2002","journal-title":"J Immunol"},{"key":"pone.0283489.ref009","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/immu.200390025","article-title":"Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit","volume":"33","author":"PA Phipps","year":"2003","journal-title":"Eur J Immunol"},{"key":"pone.0283489.ref010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2249.2004.02520.x","article-title":"Oral tolerization with peptide 336\u2013351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet\u2019s disease","volume":"137","author":"M Stanford","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"pone.0283489.ref011","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2036.2009.04185.x","article-title":"Clinical trial: the safety and short-term efficacy of recombinant cholera toxin B subunit in the treatment of active Crohn\u2019s disease","volume":"31","author":"P St\u00e5l","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0283489.ref012","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.imbio.2010.07.008","article-title":"Differential expression of toll-like receptor signaling cascades in LPS-tolerant human peripheral blood mononuclear cells","volume":"216","author":"ME Mendes","year":"2011","journal-title":"Immunobiology"},{"key":"pone.0283489.ref013","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.4049\/jimmunol.1001952","article-title":"Endotoxin tolerance represents a distinctive state of alternative polarization (M2) in human mononuclear cells","volume":"186","author":"OM Pena","year":"2011","journal-title":"J Immunol"},{"key":"pone.0283489.ref014","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00011-007-6116-4","article-title":"LPS pretreatment by the oral route protects against sepsis induced by cecal ligation and puncture. Regulation of proinflammatory response and IgM anti-LPS antibody production as associated mechanisms","volume":"56","author":"R M\u00e1rquez-Velasco","year":"2007","journal-title":"Inflamm Res"},{"key":"pone.0283489.ref015","author":"M Hanson","journal-title":"Methods and compositions for preventing and\/or treating autoimmune diseases"},{"key":"pone.0283489.ref016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cellimm.2019.03.003","article-title":"LPS enhances CTB-INSULIN induction of IDO1 and IL-10 synthesis in human dendritic cells","volume":"338","author":"N-S Kim","year":"2019","journal-title":"Cell Immunol"},{"key":"pone.0283489.ref017","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/mi.2016.95","article-title":"Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon","volume":"10","author":"KJ Baldauf","year":"2017","journal-title":"Mucosal Immunol"},{"key":"pone.0283489.ref018","article-title":"Repeated Oral Administration of a KDEL-tagged Recombinant Cholera Toxin B Subunit Effectively Mitigates DSS Colitis Despite a Robust Immunogenic Response","author":"JM Royal","year":"2019","journal-title":"Toxins (Basel)"},{"key":"pone.0283489.ref019","doi-asserted-by":"crossref","first-page":"G1328","DOI":"10.1152\/ajpgi.00467.2004","article-title":"Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL\/6 but not in BALB\/c mice: correlation between symptoms and inflammation","volume":"288","author":"S Melgar","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"pone.0283489.ref020","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/nprot.2017.044","article-title":"Chemically induced mouse models of acute and chronic intestinal inflammation","volume":"12","author":"S Wirtz","year":"2017","journal-title":"Nat Protoc"},{"key":"pone.0283489.ref021","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2249.1998.00728.x","article-title":"Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines","volume":"114","author":"LA Dieleman","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"pone.0283489.ref022","doi-asserted-by":"crossref","first-page":"13527","DOI":"10.1096\/fj.201901255R","article-title":"A modified cholera toxin B subunit containing an ER retention motif enhances colon epithelial repair via an unfolded protein response","volume":"33","author":"JM Royal","year":"2019","journal-title":"FASEB J"},{"key":"pone.0283489.ref023","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1080\/21645515.2021.1884475","article-title":"Immunogenicity of cholera vaccination in children with inflammatory bowel disease","volume":"17","author":"\u0141 Dembi\u0144ski","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0283489.ref024","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.3748\/wjg.v23.i33.6016","article-title":"Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis","volume":"23","author":"DD Eichele","year":"2017","journal-title":"World J Gastroenterol"},{"key":"pone.0283489.ref025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-1-61779-527-5_19","article-title":"T cell transfer model of colitis: a great tool to assess the contribution of T cells in chronic intestinal inflammation","volume":"844","author":"R Eri","year":"2012","journal-title":"Methods Mol Biol"},{"key":"pone.0283489.ref026","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jcmgh.2015.01.006","article-title":"Experimental Models of Inflammatory Bowel Diseases","volume":"1","author":"P Kiesler","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"pone.0283489.ref027","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11886-021-01484-5","article-title":"Drug Repurposing: Claiming the Full Benefit from Drug Development","volume":"23","author":"E Kort","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"pone.0283489.ref028","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections","volume":"128","author":"ES Larsen","year":"2020","journal-title":"APMIS"},{"key":"pone.0283489.ref029","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"H Petousis-Harris","year":"2017","journal-title":"The Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:29:22Z","timestamp":1693229362000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283489"}},"subtitle":[],"editor":[{"given":"Imad","family":"Al Kassaa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0283489","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.03.13.532404","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}